Gismo Therapeutics

Gismo Therapeutics, founded in 2011 and based in Lexington, United States, is a privately funded biotech startup focused on developing innovative oral treatments for Alzheimer's and Parkinson's Disease. The company targets fundamental biochemical processes implicated in the pathogenesis of these neurodegenerative diseases, leveraging a novel hypothesis and mechanism of action. Their core mission is to create first-in-class, disease-modifying therapeutics that can significantly alter the course of these debilitating conditions.

Notable achievements for Gismo Therapeutics include securing several prestigious research grants to advance their groundbreaking technology, known as GISMO. This technology is based on a new understanding of the etiology of major neurodegenerative amyloid diseases. The company’s impact is marked by its potential to revolutionize treatment paradigms for Alzheimer's and Parkinson's Disease, offering hope for more effective management and improved patient outcomes.